Citizens Maintains Market Outperform on Cytokinetics, Raises Price Target to $88

Benzinga · 12/22/2025 12:26
Citizens analyst Jason Butler maintains Cytokinetics (NASDAQ:CYTK) with a Market Outperform and raises the price target from $78 to $88.